 - Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date of March 21, 2021 - - Clinical data expected in 1H 2021 from KPL-404 anti-CD40 Phase 1 clinical trial and mavrilimumab Phase 2 clinical trial in severe COVID-19 - - Year-end 2020 cash reserves of approximately 323 million - 